α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
NKT cells are CD1d-restricted innate-like T cells expressing both T cell receptor and NK cell markers. The major group of NKT cells in both human and mice is the invariant NKT (iNKT) cells and the best-known function of iNKT cells is their potent anti-tumor function in mice. Since its discovery 25 y...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01126/full |
| _version_ | 1818565684359069696 |
|---|---|
| author | Yingting Zhang Ryan Springfield Siyang Chen Xin Li Xiaotian Feng Rosa Moshirian Rirong Yang Weiming Yuan |
| author_facet | Yingting Zhang Ryan Springfield Siyang Chen Xin Li Xiaotian Feng Rosa Moshirian Rirong Yang Weiming Yuan |
| author_sort | Yingting Zhang |
| collection | DOAJ |
| description | NKT cells are CD1d-restricted innate-like T cells expressing both T cell receptor and NK cell markers. The major group of NKT cells in both human and mice is the invariant NKT (iNKT) cells and the best-known function of iNKT cells is their potent anti-tumor function in mice. Since its discovery 25 years ago, the prototype ligand of iNKT cells, α-galactosylceramide (α-GalCer) has been used in over 30 anti-tumor clinical trials with mostly suboptimal outcomes. To realize its therapeutic potential, numerous preclinical models have been developed to optimize the scheme and strategies for α-GalCer-based cancer immunotherapies. Nevertheless, since there is no standard protocol for α-GalCer delivery, we reviewed the preclinical studies with a focus on B16 melanoma model in the goal of identifying the best treatment schemes for α-GalCer treatment. We then reviewed the current progress in developing more clinically relevant mouse models for these preclinical studies, most notably the generation of new mouse models with a humanized CD1d/iNKT cell system. With ever-emerging novel iNKT cell ligands, invention of novel α-GalCer delivery strategies and significantly improved preclinical models for optimizing these new strategies, one can be hopeful that the full potential of anti-tumor potential for α-GalCer will be realized in the not too distant future. |
| first_indexed | 2024-12-14T01:44:17Z |
| format | Article |
| id | doaj.art-e21f1482184140db858d9095abb4c39a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-14T01:44:17Z |
| publishDate | 2019-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e21f1482184140db858d9095abb4c39a2022-12-21T23:21:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-06-011010.3389/fimmu.2019.01126449638α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic PotentialsYingting ZhangRyan SpringfieldSiyang ChenXin LiXiaotian FengRosa MoshirianRirong YangWeiming YuanNKT cells are CD1d-restricted innate-like T cells expressing both T cell receptor and NK cell markers. The major group of NKT cells in both human and mice is the invariant NKT (iNKT) cells and the best-known function of iNKT cells is their potent anti-tumor function in mice. Since its discovery 25 years ago, the prototype ligand of iNKT cells, α-galactosylceramide (α-GalCer) has been used in over 30 anti-tumor clinical trials with mostly suboptimal outcomes. To realize its therapeutic potential, numerous preclinical models have been developed to optimize the scheme and strategies for α-GalCer-based cancer immunotherapies. Nevertheless, since there is no standard protocol for α-GalCer delivery, we reviewed the preclinical studies with a focus on B16 melanoma model in the goal of identifying the best treatment schemes for α-GalCer treatment. We then reviewed the current progress in developing more clinically relevant mouse models for these preclinical studies, most notably the generation of new mouse models with a humanized CD1d/iNKT cell system. With ever-emerging novel iNKT cell ligands, invention of novel α-GalCer delivery strategies and significantly improved preclinical models for optimizing these new strategies, one can be hopeful that the full potential of anti-tumor potential for α-GalCer will be realized in the not too distant future.https://www.frontiersin.org/article/10.3389/fimmu.2019.01126/fulliNKT cellcancer immonotherapypreclinical modelinghumanized miceα-GalCer |
| spellingShingle | Yingting Zhang Ryan Springfield Siyang Chen Xin Li Xiaotian Feng Rosa Moshirian Rirong Yang Weiming Yuan α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials Frontiers in Immunology iNKT cell cancer immonotherapy preclinical modeling humanized mice α-GalCer |
| title | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| title_full | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| title_fullStr | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| title_full_unstemmed | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| title_short | α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials |
| title_sort | α galcer and inkt cell based cancer immunotherapy realizing the therapeutic potentials |
| topic | iNKT cell cancer immonotherapy preclinical modeling humanized mice α-GalCer |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.01126/full |
| work_keys_str_mv | AT yingtingzhang agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT ryanspringfield agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT siyangchen agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT xinli agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT xiaotianfeng agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT rosamoshirian agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT rirongyang agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials AT weimingyuan agalcerandinktcellbasedcancerimmunotherapyrealizingthetherapeuticpotentials |